Evidence map›Paper›PMID 41909506›Full record

ArticleBioactive materials2026

Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway.

Binhua Zou, Shuoshan Li, Kar-Him Luk, Xiaoli Dong, Nathanael Chun-Him Lai, Wai-Yin Cheng, Gang Liu, Ka-Hing Wong, Tianfeng Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Binhua ZouDepartment of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
Shuoshan LiDepartment of Chemistry and Institute of Nanotechnology and Intelligence (inAI) of Jinan University, Department of Radiation Oncology of Puning People's Hospital (Guangdong Postdoctoral Innovation Practice Base of Jinan University), State Key Laboratory of Bioactive Molecules and Druggalibility Assessment, Jinan University, Guangdong, PR China.
Kar-Him LukResearch Institute for Future Food, Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region of China.
Xiaoli DongResearch Institute for Future Food, Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region of China.
Nathanael Chun-Him LaiResearch Institute for Future Food, Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region of China.
Wai-Yin ChengResearch Institute for Future Food, Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region of China.
Gang LiuDepartment of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.
Ka-Hing WongResearch Institute for Future Food, Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region of China.
Tianfeng ChenDepartment of Rehabilitation Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is characterized by aggressive biological behavior, including rapid post-treatment recurrence propensity, heightened metastatic dissemination, and significantly diminished survival outcomes. These features emphasize the necessity for innovative therapeutic strategies in TNBC treatment. Herein, we developed selenium nanoparticles modified with a mushroom polysaccharide-protein complex (PTR-SeNPs) and evaluated them

Indexed as

ApoptosisMucin 1SeleniumSelenium nanoparticlesSelenoproteinTriple-negative breast cancer

Identifiers

PMID41909506
PMCPMC13020000

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.